The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.

AIMS: Anaemia and iron deficiency are constituents of the cardio-renal syndrome in chronic heart failure (CHF). We investigated the effects of i.v. iron in iron-deficient CHF patients on renal function, and the efficacy and safety of this therapy in patients with renal dysfunction. METHODS AND RESUL...

ver descrição completa

Detalhes bibliográficos
Autores: Ponikowski, Piotr, Filippatos, Gerasimos, Comín Colet, Josep, Willenheimer, Ronnie, Dickstein, Kenneth, Lüscher, Thomas F., Gaudesius, Giedrius, von Eisenhart Rothe, Barbara, Mori, Claudio, Greenlaw, Nicola, Ford, Ian, Macdougall, Iain, Anker, Stefan D., FAIR-HF Trial Investigators
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2015
País:España
Recursos:Universitat Pompeu Fabra
Repositório:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/26121
Acesso em linha:http://hdl.handle.net/10230/26121
http://dx.doi.org/10.1002/ejhf.229
Access Level:Acceso aberto
Palavra-chave:Insuficiència cardíaca
Aparell urinari -- Fisiologia
id ES_21676f49efe37ae5d60eb60aff2f59e7
oai_identifier_str oai:repositori.upf.edu:10230/26121
network_acronym_str ES
network_name_str España
repository_id_str
spelling The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.Ponikowski, PiotrFilippatos, GerasimosComín Colet, JosepWillenheimer, RonnieDickstein, KennethLüscher, Thomas F.Gaudesius, Giedriusvon Eisenhart Rothe, BarbaraMori, ClaudioGreenlaw, NicolaFord, IanMacdougall, IainAnker, Stefan D.FAIR-HF Trial InvestigatorsInsuficiència cardíacaAparell urinari -- FisiologiaAIMS: Anaemia and iron deficiency are constituents of the cardio-renal syndrome in chronic heart failure (CHF). We investigated the effects of i.v. iron in iron-deficient CHF patients on renal function, and the efficacy and safety of this therapy in patients with renal dysfunction. METHODS AND RESULTS: The FAIR-HF trial randomized 459 CHF patients with iron deficiency (ferritin <100 µg/L, or between 100 and 299 µg/L if transferrin saturation was <20%): 304 to i.v. ferric carboxymaltose (FCM) and 155 to placebo, and followed-up for 24 weeks. Renal function was assessed at baseline and at weeks 4, 12, and 24, using the estimated glomerular filtration rate (eGFR, mL/min/1.73 m(2) ), calculated from the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. At baseline, renal function was similar between groups (62.4 ± 20.6 vs. 62.9 ± 23.4 mL/min/1.73 m(2) , FCM vs. placebo). Compared with placebo, treatment with FCM was associated with an increase in eGFR [treatment effect: week 4, 2.11 ± 1.21 (P = 0.082); week 12, 2.41 ± 1.33 (P = 0.070); and week 24, 2.98 ± 1.44 mL/min/1.73 m(2) (P = 0.039)]. This effect was seen in all pre-specified subgroups (P > 0.20 for interactions). No interaction between the favourable effects of FCM and baseline renal function was seen for the primary endpoints [improvement in Patient Global Assessment (P = 0.43) and NYHA class (P = 0.37) at 24 weeks]. Safety and adverse event profiles were similar in patients with baseline eGFR <60 and ≥60 mL/min/1.73 m(2) . CONCLUSIONS: Treatment of iron deficiency in CHF patients with i.v. FCM was associated with an improvement in renal function. FCM therapy was effective and safe in CHF patients with renal dysfunction.The FAIR-HF study and this analysis were supported by Vifor Pharma, Zurich, Switzerland.Oxford University Press201620162015info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/26121http://dx.doi.org/10.1002/ejhf.229reponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglésEuropean Journal of Heart Failure. 2015 Mar;17(3):329-39©2015 The Authors.European Journal of Heart Failurepublished by John Wiley & Sons Ltd on behalf of European Society of Cardiology.This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/, which permits use anddistribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/261212026-06-12T07:21:37Z
dc.title.none.fl_str_mv The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.
title The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.
spellingShingle The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.
Ponikowski, Piotr
Insuficiència cardíaca
Aparell urinari -- Fisiologia
title_short The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.
title_full The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.
title_fullStr The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.
title_full_unstemmed The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.
title_sort The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.
dc.creator.none.fl_str_mv Ponikowski, Piotr
Filippatos, Gerasimos
Comín Colet, Josep
Willenheimer, Ronnie
Dickstein, Kenneth
Lüscher, Thomas F.
Gaudesius, Giedrius
von Eisenhart Rothe, Barbara
Mori, Claudio
Greenlaw, Nicola
Ford, Ian
Macdougall, Iain
Anker, Stefan D.
FAIR-HF Trial Investigators
author Ponikowski, Piotr
author_facet Ponikowski, Piotr
Filippatos, Gerasimos
Comín Colet, Josep
Willenheimer, Ronnie
Dickstein, Kenneth
Lüscher, Thomas F.
Gaudesius, Giedrius
von Eisenhart Rothe, Barbara
Mori, Claudio
Greenlaw, Nicola
Ford, Ian
Macdougall, Iain
Anker, Stefan D.
FAIR-HF Trial Investigators
author_role author
author2 Filippatos, Gerasimos
Comín Colet, Josep
Willenheimer, Ronnie
Dickstein, Kenneth
Lüscher, Thomas F.
Gaudesius, Giedrius
von Eisenhart Rothe, Barbara
Mori, Claudio
Greenlaw, Nicola
Ford, Ian
Macdougall, Iain
Anker, Stefan D.
FAIR-HF Trial Investigators
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Insuficiència cardíaca
Aparell urinari -- Fisiologia
topic Insuficiència cardíaca
Aparell urinari -- Fisiologia
description AIMS: Anaemia and iron deficiency are constituents of the cardio-renal syndrome in chronic heart failure (CHF). We investigated the effects of i.v. iron in iron-deficient CHF patients on renal function, and the efficacy and safety of this therapy in patients with renal dysfunction. METHODS AND RESULTS: The FAIR-HF trial randomized 459 CHF patients with iron deficiency (ferritin <100 µg/L, or between 100 and 299 µg/L if transferrin saturation was <20%): 304 to i.v. ferric carboxymaltose (FCM) and 155 to placebo, and followed-up for 24 weeks. Renal function was assessed at baseline and at weeks 4, 12, and 24, using the estimated glomerular filtration rate (eGFR, mL/min/1.73 m(2) ), calculated from the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. At baseline, renal function was similar between groups (62.4 ± 20.6 vs. 62.9 ± 23.4 mL/min/1.73 m(2) , FCM vs. placebo). Compared with placebo, treatment with FCM was associated with an increase in eGFR [treatment effect: week 4, 2.11 ± 1.21 (P = 0.082); week 12, 2.41 ± 1.33 (P = 0.070); and week 24, 2.98 ± 1.44 mL/min/1.73 m(2) (P = 0.039)]. This effect was seen in all pre-specified subgroups (P > 0.20 for interactions). No interaction between the favourable effects of FCM and baseline renal function was seen for the primary endpoints [improvement in Patient Global Assessment (P = 0.43) and NYHA class (P = 0.37) at 24 weeks]. Safety and adverse event profiles were similar in patients with baseline eGFR <60 and ≥60 mL/min/1.73 m(2) . CONCLUSIONS: Treatment of iron deficiency in CHF patients with i.v. FCM was associated with an improvement in renal function. FCM therapy was effective and safe in CHF patients with renal dysfunction.
publishDate 2015
dc.date.none.fl_str_mv 2015
2016
2016
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/26121
http://dx.doi.org/10.1002/ejhf.229
url http://hdl.handle.net/10230/26121
http://dx.doi.org/10.1002/ejhf.229
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv European Journal of Heart Failure. 2015 Mar;17(3):329-39
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Oxford University Press
publisher.none.fl_str_mv Oxford University Press
dc.source.none.fl_str_mv reponame:Repositorio Digital de la UPF
instname:Universitat Pompeu Fabra
instname_str Universitat Pompeu Fabra
reponame_str Repositorio Digital de la UPF
collection Repositorio Digital de la UPF
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869404513825193984
score 15.811543

Registros relacionados